Modality
mRNA
MOA
STINGag
Target
PCSK9
Pathway
Fibrosis
MMPsoriasisOCD
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
Feb 2019
→ Mar 2029
Phase 2Current
NCT05940630
2,316 pts·MM
2022-09→TBD·Terminated
NCT05119603
1,238 pts·Psoriasis
2019-02→2029-03·Active
3,554 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-243.0y awayPh2 Data· Psoriasis
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2029-03-24 · 3.0y away
Psoriasis
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05940630 | Phase 2 | MM | Terminated | 2316 | VA |
| NCT05119603 | Phase 2 | Psoriasis | Active | 1238 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |